Hemophilia A
ORPHA:98878DiseaseX-linked recessiveChildhood, Infancy, Neonatal
Фенотипы (HPO)14
Очень частый (80–99%)4
HP:0001386Joint swelling
HP:0002829Arthralgia
HP:0003125Reduced factor VIII activity
HP:0011889Bleeding with minor or no trauma
Частый (30–79%)3
HP:0001907Thromboembolism
HP:0007420Spontaneous hematomas
HP:0030140Oral cavity bleeding
Периодический (5–29%)5
HP:0005261Joint hemorrhage
HP:0002239Gastrointestinal hemorrhage
HP:0009811Abnormality of the elbow
HP:0012233Intramuscular hematoma
HP:0030746Intraventricular hemorrhage
Очень редкий (1–4%)2
HP:0002170Intracranial hemorrhage
HP:0012223Splenic rupture
Эпидемиология110
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 4.85 | Worldwide | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 11.25 | Worldwide | Value and class |
| Point prevalence | 1-5 / 10 000 | 10.5 | France | Value and class |
| Point prevalence | 1-9 / 100 000 | 7 | United States | Value and class |
| Point prevalence | 1-9 / 100 000 | 8 | Europe | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.58 | Africa | Value and class |
| Point prevalence | 1-9 / 100 000 | 7.6 | Albania | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.8 | Algeria | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.5 | Argentina | Value and class |
| Point prevalence | 1-9 / 100 000 | 5 | Armenia | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.8 | Australia | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.3 | Austria | Value and class |
| Point prevalence | 1-9 / 100 000 | 8 | Azerbaijan | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.2 | Bangladesh | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.1 | Belarus | Value and class |
| Point prevalence | 1-9 / 100 000 | 6 | Belgium | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.2 | Belize | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1 | Bolivia | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.6 | Bosnia and Herzegovina | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.7 | Brazil | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.8 | Bulgaria | Value and class |
| Point prevalence | 1-9 / 100 000 | 7.3 | Canada | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.3 | Chile | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.2 | China | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.6 | Colombia | Value and class |
| Point prevalence | 1-9 / 100 000 | 3 | Costa rica | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.5 | Croatia | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.7 | Cuba | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.2 | Cyprus | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.1 | Czech Republic | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.2 | Denmark | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.8 | Dominican Republic | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.5 | Ecuador | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.4 | Egypt | Value and class |
| Point prevalence | 1-9 / 100 000 | 3 | El Salvador | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.7 | Eritrea | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.8 | Estonia | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.6 | Finland | Value and class |
| Point prevalence | 1-9 / 100 000 | 5 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.5 | Greece | Value and class |
| Point prevalence | 1-9 / 100 000 | 1 | Guatemala | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.6 | Honduras | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.3 | Hungary | Value and class |
| Point prevalence | 1-5 / 10 000 | 19.3 | Iceland | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.7 | India | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1 | Indonesia | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.6 | Iran, Islamic Republic of | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.8 | Iraq | Value and class |
| Point prevalence | 1-9 / 100 000 | 9.2 | Ireland | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.4 | Israel | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.7 | Italy | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.6 | Jamaica | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.3 | Japan | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.5 | Jordan | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.1 | Kenya | Value and class |
| Point prevalence | 1-9 / 100 000 | 3 | Korea, Republic of | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.9 | Latvia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.5 | Lebanon | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.7 | Lesotho | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.1 | Lithuania | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.4 | Luxembourg | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.1 | North Macedonia | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.3 | Malaysia | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.3 | Malta | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.2 | Mexico | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.7 | Moldova, Republic of | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.4 | Mongolia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1 | Morocco | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.6 | Nepal | Value and class |
| Point prevalence | 1-9 / 100 000 | 9.3 | Netherlands | Value and class |
| Point prevalence | 1-5 / 10 000 | 11 | New Zealand | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.7 | Nicaragua | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.025 | Nigeria | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.1 | Norway | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.8 | Pakistan | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.7 | Palestinian Territory, occupied | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.6 | Panama | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.2 | Paraguay | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.6 | Peru | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.9 | Philippines | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.6 | Poland | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.9 | Portugal | Value and class |
| Point prevalence | 1-9 / 100 000 | 7.9 | Qatar | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.4 | Romania | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.3 | Russian Federation | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.5 | Saudi Arabia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.8 | Senegal | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.7 | Serbia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1 | Sierra leone | Value and class |
| Point prevalence | 1-9 / 100 000 | 4 | Singapore | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.6 | Slovakia | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.2 | Slovenia | Value and class |
| Point prevalence | 1-9 / 100 000 | 3 | South Africa | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.8 | Spain | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.6 | Sri Lanka | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.85 | Sudan | Value and class |
| Point prevalence | 1-9 / 100 000 | 7.7 | Sweden | Value and class |
| Point prevalence | 1-9 / 100 000 | 7.1 | Switzerland | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.8 | Thailand | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.02 | Togo | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.2 | Tunisia | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.1 | Turkey | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.35 | Ukraine | Value and class |
| Point prevalence | 1-5 / 10 000 | 10.4 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.9 | Uruguay | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.8 | Uzbekistan | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.9 | Venezuela | Value and class |
| Point prevalence | 1-9 / 100 000 | 1 | Viet Nam | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.3 | Zimbabwe | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.4 | Georgia | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)